Study | Public year | Country | HP (+ vs. −) | CagA (+ vs. −) | Results | ||||
---|---|---|---|---|---|---|---|---|---|
Population | Conc | PR (%) | Population | Conc | PR (%) | ||||
Moretti [9] | 2017 | Italy | 32 vs. 41 | 38.0 vs. 55.0* | 17 .0 vs. 34.0*** | 20 vs. 12 | 33.4 vs. 42.5 | 10.5 vs. 22.5*** | HP+ reduced conc. and PR |
Moretti [17] | 2015 | Italy | 28 vs.81 | 61 vs. 72 | 32 vs. 32 | 12 vs. 16 | 61 vs. 61.5 | 24 vs. 36.5* | CagA+ reduce PR |
El-Garem [18] | 2014 | Egypt | NA | NA | NA | 22 vs. 201 | NA | NA | HP treatment improved PR |
Moretti [16] | 2013 | Italy | NA | NA | NA | 37 vs. 50 | 58 vs. 63 | 18 vs. 32** | CagA+ reduced PR |
Moretti [7] | 2012 | Italy | 27 vs. 51 | 94 vs. 72 | 32 vs. 30 | 11 vs. 16 | 65 vs. 94 | 24 vs. 38** | CagA+ reduced PR |
Collodel [6] | 2010 | Italy | 36 vs.44 | 24.5 vs. 23.5 | 22 vs. 28.5 | 17 vs. 19 | 25.5 vs. 23 | 18 vs. 29* | CagA+ reduced PR |